Rubedo.Life
Stage: Series A, Pre-clinical - lead optimisation
Area: Drug discovery platform
Status: Ongoing
Patent: Patents acquired
Background
Rubedo has started developing therapeutics for idiopathic pulmonary fibrosis (IPF) and lung cancer. IPF is an orphan disease, with a potentially accelerated clearance by the FDA. They work with published and proprietary databases that they have generated in-house.
Rubedo’s proprietary ALEMBIC™ drug discovery platform is based on a synergy between sophisticated computational and chemistry strategies.
This hybrid platform enables the discovery and development of novel first-in-class engineered small molecules, such as prodrugs, designed to selectively target certain types of “bad” cells, like senescent cells, which play a key role in the progression of chronic disorders.
Aims, Hypothesis & Results
The team has identified a portfolio of small molecules that target signature metabolism features of rare (presumably pathogenic) cells and are currently working to test and optimize these compounds in preclinical models.
Timeline
Pre-Clinical Studies: Lead Optimisation for 4 drugs in the pipeline
VitaDAO Board Evaluation Writeup
This platform has a high potential for impact since it can be applied to a wide variety of cellular phenomena ranging from eliminating pathogenic cells, regenerating stem cells, removing ECM debris, repairing mitochondria, etc.Focusing on prodrugs is a valuable approach since it allows for the delivery of drugs to be highly cell-specific and avoid off-target effects.
Their successful proof-of-concept for targeting cellular senescence is a great example of this and shows strong in vivo results with virtually no off-target effectsHowever, it has yet to be seen if they will be as successful in targeting other cellular phenomena as they are with cellular senescence. Also, it is still unclear how these prodrugs will be delivered in vivo and what their plan is to address this, but I don’t see this as a major hindrance to the company’s success at this stage. Overall, Rubedo’s workflow is logical and feasible - from target discovery in silico, moving to in vitro testing, and finally in vivo - and the ALEMBIC platform is very promising for the longevity field, and possibly other fields as well
Non Consectetur Necessitatibus
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Eum Harum Asperiores Id
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Ex Temporibus Perferendis
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Dolorum Quia
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Earum Est Dolorem
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Culpa Possimus
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Aperiam Et Quis Et
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Voluptas Quam Sapiente
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut Accusantium Ut
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Nisi
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Discover more projects & initiatives
Humanity
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.
Matrix Bio
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.
BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.
ExcepGen Inc - RNA therapeutics for longevity
ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.
Are you working on the next longevity science breakthrough?
Apply for fundingAbout VitaDAO
